Intellus Advisors’s AbbVie ABBV Stock Holding History

Intellus Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$974K	Sell	3,871 -126	-3%	-$27.1K	0.12%	52
2026 Q1	$869K	Buy	3,997 +73	+2%	+$16.2K	0.12%	53
2025 Q4	$897K	Sell	3,924 -438	-10%	-$99.8K	0.12%	54
2025 Q3	$1.01M	Hold	4,362	–	–	0.14%	48
2025 Q2	$810K	Buy	4,362 +248	+6%	+$46.1K	0.12%	57
2025 Q1	$862K	Hold	4,114	–	–	0.15%	51
2024 Q4	$731K	Buy	+4,114	New	+$756K	0.13%	61

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Intellus Advisors's ABBV Position: Q2 2026 in Review

Intellus Advisors reduced its AbbVie (ABBV) stake by 3.2% in Q2 2026, selling an estimated $27.1K and leaving 3,871 shares worth $974K. The position accounts for 0.12% of the portfolio, ranked #52.

Intellus Advisors first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.01M in Q3 2025. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Intellus Advisors held 3,871 shares of AbbVie worth $974K as of Q2 2026.
Intellus Advisors sold 126 AbbVie shares in Q2 2026, an estimated $27.1K.
AbbVie made up 0.12% of Intellus Advisors's portfolio in Q2 2026, its #52 holding.
Intellus Advisors first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
Intellus Advisors's AbbVie position peaked at $1.01M in Q3 2025.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Intellus Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.